LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Search

Erasca Inc

Closed

2.88 -1.37

Overview

Share price change

24h

Current

Min

2.88

Max

3

Key metrics

By Trading Economics

Income

3.3M

-31M

EPS

-0.11

Profit margin

-768.16

Employees

103

EBITDA

8.3M

-30M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+54.11% upside

Market Stats

By TradingEconomics

Market Cap

165M

814M

Previous open

4.25

Previous close

2.88

Technical Score

By Trading Central

Confidence

Bearish Evidence

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Nov 2025, 21:54 UTC

Acquisitions, Mergers, Takeovers

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175 Million

24 Nov 2025, 18:26 UTC

Major Market Movers

Tegna Shares Fall After Trump Blasts Proposal to Lift Broadcast Ownership Cap

24 Nov 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Tech Recovery on Wall Street -- Market Talk

24 Nov 2025, 23:08 UTC

Market Talk

More Losses Ahead for Steel & Tube, Says New Bear -- Market Talk

24 Nov 2025, 23:08 UTC

Market Talk

Global Equities Roundup: Market Talk

24 Nov 2025, 22:56 UTC

Market Talk
Earnings

Alimentation Couche-Tard U.S. Sales Gain Momentum -- Market Talk

24 Nov 2025, 22:47 UTC

Market Talk

Kiwi Property Can Keep Growing Its Dividend -- Market Talk

24 Nov 2025, 22:36 UTC

Market Talk
Earnings

Kiwi Property's 1H Result Cements Bull's Confidence in Outlook -- Market Talk

24 Nov 2025, 22:32 UTC

Earnings

Webco Industries 1Q EPS $6.79 >WEBC

24 Nov 2025, 22:07 UTC

Earnings

Couche-Tard 2Q Canada Same-Store Merchandise Revenues Up 5.4% >ATD.T

24 Nov 2025, 22:07 UTC

Earnings

Couche-Tard 2Q U.S. Same-Store Merchandise Revenues Up 1.2% >ATD.T

24 Nov 2025, 22:06 UTC

Earnings

Couche-Tard 2Q Adj EPS 78c >ATD.T

24 Nov 2025, 22:06 UTC

Earnings

Couche-Tard 2Q Rev $17.9B >ATD.T

24 Nov 2025, 22:06 UTC

Earnings

Couche-Tard 2Q EPS 79c >ATD.T

24 Nov 2025, 22:05 UTC

Earnings

Couche-Tard 2Q Rev $17.9B >ATD.T

24 Nov 2025, 22:05 UTC

Earnings

Couche-Tard 2Q Net $740.6M >ATD.T

24 Nov 2025, 22:05 UTC

Earnings

Couche-Tard 2Q Adj EPS 78c >ATD.T

24 Nov 2025, 22:05 UTC

Earnings

Couche-Tard 2Q EPS 79c >ATD.T

24 Nov 2025, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

24 Nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

24 Nov 2025, 21:44 UTC

Market Talk

Canada Close to MOU With Alberta About New Possible Pipeline -- Market Talk

24 Nov 2025, 21:39 UTC

Acquisitions, Mergers, Takeovers

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175M

24 Nov 2025, 20:42 UTC

Market Talk

Oil Futures Snap Three-Session Losing Streak -- Market Talk

24 Nov 2025, 20:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

24 Nov 2025, 19:56 UTC

Acquisitions, Mergers, Takeovers

Nvidia Says It's Not Enron in Private Memo Refuting Accounting Questions -- Barrons.com

24 Nov 2025, 18:26 UTC

Market Talk

Crude Futures Move Higher in Choppy Trade -- Market Talk

24 Nov 2025, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

24 Nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

24 Nov 2025, 17:09 UTC

Market Talk

Brent Could Drop to the $30s Without Production Cuts, JPM Says -- Market Talk

24 Nov 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

Strategy Silent on Bitcoin Holdings. Why It's a Big Deal for the Stock and Cryptos. -- Barrons.com

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

54.11% upside

12 Months Forecast

Average 4.5 USD  54.11%

High 6 USD

Low 1 USD

Based on 4 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

1.39 / 1.44Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Very Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat